News

manilatimes21d
UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers
Chief Medical Officer (Adult Cancers), UTRx Inc. "The validation data supports the technological abilities of engineering mRNA stability elements on the 3'UTR of oncogenes for therapeutic use,” said ...
BioSpace21d
UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers
Chief Medical Officer (Adult Cancers), UTRx Inc. “The validation data supports the technological abilities of engineering mRNA stability elements on the 3’UTR of oncogenes for therapeutic use,” said ...
KELOLAND News21d
UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers
Chief Medical Officer (Adult Cancers), UTRx Inc. “The validation data supports the technological abilities of engineering mRNA stability elements on the 3’UTR of oncogenes for therapeutic use ...
The Hamilton Spectator22d
UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — UTR Therapeutics Inc (UTRx Inc.), a drug development biotech company based in New York City, USA is pleased to announce a new milestone, the submission ...
The EMBO Journal3mon
Pumilio differentially binds to mRNA 3′ UTR isoforms to regulate localization of synaptic proteins
These longer 3′ UTRs tend to remain in the neuronal soma, whereas shorter UTR isoforms localize to the synapse. In cultured pumilio mutant neurons, axon outgrowth defects are accompanied by mRNA ...